Abacavir Sulfate: CAS Registry Number 188062-50-2

Abacavir sulfate, chemically defined as CAS number 188062-50-2, acts as a highly effective HIV medication. It blocks the proliferation of the human immunodeficiency virus (HIV) by stopping the viral enzyme reverse transcriptase. This enzyme is essential in the HIV life cycle, enabling the virus to insert its genetic material into the host's DNA. Ab

read more

Pharmacological Properties of Abacavir Sulfate (188062-50-2)

Abacavir sulfate is a nucleoside reverse transcriptase inhibitor utilized in the therapy of human immunodeficiency virus disease. Its therapeutic properties involve the competitive inhibition of reverse transcriptase, an enzyme essential for HIV replication. Abacavir sulfate is a pro-drug that transits modification to its active form, carbovir, wi

read more

Premier API Manufacturer & Supplier

In today's rapidly evolving technological landscape, reliable and high-performance APIs are essential for businesses of all sizes. The premier global API manufacturer and supplier offers a comprehensive portfolio of cutting-edge APIs designed to meet the diverse needs of modern applications. With a strong commitment to quality, innovation, and cust

read more

Pharmacological Properties of Abacavir Sulfate (188062-50-2)

Abacavir sulfate is a nucleotide reverse transcriptase inhibitor. Its mechanism of action involves the competitive suppression of HIV-1 reverse transcriptase, an enzyme crucial for viral replication. Abacavir sulfate exerts its influence by being incorporated into the growing DNA chain during reverse transcription, leading to premature stopping. Th

read more

A Top Nutraceutical API Manufacturer

India has firmly established itself as a global hub for nutraceutical ingredient creation, particularly in the realm of Active Pharmaceutical Ingredients (APIs). Numerous domestic firms specialize in the custom synthesis of nutraceutical compounds, serving both the local market and exporting globally. These businesses boast advanced infrastructure,

read more